Editor's Note Preliminary research shows removing breasts or ovaries can significantly improve survival and reduce recurrence risk in young breast cancer patients with BRCA mutations, HealthDay reported December 13. The findings were presented this week at the San Antonio Breast Cancer Symposium. According to the article, researchers analyzed data from…
Editor's Note Active monitoring for certain breast cancer patients offers similar outcomes to surgery with fewer side effects, according to research detailed in a December 16 article from Oncology News Central. Presented at the 2024 San Antonio Breast Cancer Symposium and published in JAMA, The COMET trial supports the safety…
Editor's Note Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative early breast cancer provides noninferior outcomes compared to undergoing the procedure, MedPage Today reported December 13. Presented at the San Antonio Breast Cancer Symposium and published in the New England Journal of Medicine, the INSEMA trial found…
Editor's Note Medical professionals have long accepted that bilateral mastectomy does not improve survival outcomes for breast cancer patients. However, a study published in JAMA Oncology reveals a puzzling finding: Those who develop a second cancer in the other breast have a higher risk of death. As detailed in a…
Editor's Note Artificial intelligence (AI)-fueled analysis of electronic health records suggests that clinical guidelines for de-escalating surgery should be extended to younger breast cancer patients. Conducted by University of Pittsburgh and UPMC Hillman Cancer Center researchers and published in JCO Clinical Cancer Informatics, the analysis suggests that “surgery involving sentinel…
Editor's Note An AI model that outperformed MRI and ultrasound in identifying patients with axillary breast cancer metastasis shows the technology’s potential to reduce the need for needle or surgical biopsies, according to developers at UT Southwestern Medical Center. In a May 21 report on their new AI model, researchers…
Editor's Note The US Food and Drug Administration (FDA) has designated the recall of Hologic Inc.’s BioZorb Marker a class 1, indicating a risk of serious injury or death. BioZorb is an implantable radiographic marker used to mark soft tissue (such as breast tissue) for future medical procedures. Provided sterile…
Editor's Note The US Food and Drug Administration (FDA) approved Lumisight (pegulicianine), a fluorescent imaging drug used to detect cancerous tissue during lumpectomy, on April 17. Administered intravenously prior to surgery, Lumisight is designed for use with the Lumicell Direct Visualization System (DVS) or another imaging device that is FDA-approved…
Editor's Note Online breast cancer surgery information is often difficult to understand and may be impeding people’s ability to make informed decisions about their care, US News October 25 reports. Researchers reviewed patient education materials describing breast-conserving surgery, mastectomy, and lymph node surgery from US National Cancer Institute related websites…
Editor's Note Researchers from the University of North Carolina developed an artificial intelligence (AI) model that can predict whether cancerous tissue has been fully removed from the body during breast cancer surgical procedures. Their findings were published in the Annals of Surgical Oncology August 2023 issue. During the procedure, surgeons…